Evidence map›Paper›PMID 40777750›Full record

ArticleCase reports in oncology

A Case of False-Negative Results in the One-Step Nucleic Acid Amplification Assay for Sentinel Lymph Node Metastasis in Breast Cancer with Low Cytokeratin 19 Expression.

Ai Koyanagi, Akinari Kakumoto, Hajime Kuroda, Shogo Baba, Mami Koketsu, Oi Harada, Yasutaka Kato, Hiroshi Nishihara, Hiroyuki Kawami

Abstract readCase Reports
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ai KoyanagiDepartment of Diagnostic Pathology, Tokyo Women's Medical University Adachi Medical Center, Adachi-Ku, Japan.
Akinari KakumotoDepartment of Diagnostic Pathology, Tokyo Women's Medical University Adachi Medical Center, Adachi-Ku, Japan.
Hajime KurodaDepartment of Diagnostic Pathology, Tokyo Women's Medical University Adachi Medical Center, Adachi-Ku, Japan.
Shogo BabaDepartment of Pathology and Genetics, Laboratory of Cancer Medical Science, Hokuto Hospital, Obihiro, Japan.
Mami KoketsuDepartment of Pathology and Genetics, Laboratory of Cancer Medical Science, Hokuto Hospital, Obihiro, Japan.
Oi HaradaDepartment of Pathology and Genetics, Laboratory of Cancer Medical Science, Hokuto Hospital, Obihiro, Japan.
Yasutaka KatoDepartment of Pathology and Genetics, Laboratory of Cancer Medical Science, Hokuto Hospital, Obihiro, Japan.
Hiroshi NishiharaDepartment of Pathology and Genetics, Laboratory of Cancer Medical Science, Hokuto Hospital, Obihiro, Japan.
Hiroyuki KawamiCenter for Breast Diseases and Breast Cancer, Hokuto Hospital and Clinic, Obihiro, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: One-step nucleic acid amplification (OSNA) for the analysis of sentinel lymph nodes is now widely used as a reliable tool for the intraoperative diagnosis of breast cancer metastasis based on the quantification of CK19 mRNA. However, discrepancies have been noted between the molecular diagnosis and histological evaluation, potentially due to differences in tissue sampling or technical limitations. Furthermore, false-negative results may occur when target mRNA expression is reduced. Case Presentation: We herein describe a 45-year-old female patient who underwent breast-conserving surgery. The final pathological stage after surgery was pT2N1aM0 (stage IIB), hormone receptor positive (HER2: 1+). An OSNA analysis of two sentinel lymph nodes revealed no metastasis, whereas touch imprint cytology of one of the lymph nodes was positive. Immunohistochemistry of the primary tumor showed a mixture of extensive CK19-negative and focal CK19-positive lesions. A genetic analysis of the CK19-negative lesion detected mutations and abnormalities, including the Conclusion: False-negative results are more likely to occur for CK19-negative breast cancer, emphasizing the importance of incorporating complementary diagnostic methods, such as touch imprint cytology and different molecular markers. A multifaceted diagnostic approach is crucial for ensuring accurate staging and appropriate treatment planning.

Indexed as

CK19False-negative resultsOne-step nucleic acid amplification

Identifiers

PMID40777750
PMCPMC12331226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.